Sign Up Today and Learn More About Kainova Therapeutics Stock
Invest in or calculate the value of your shares in Kainova Therapeutics or other pre-IPO companies through EquityZen's platform.
Kainova Therapeutics Stock
Kainova Therapeutics develops small molecules targeting G-coupled protein receptors.
About Kainova Therapeutics Stock
Founded
2001
Industries
Food and Beverage, Software, Artificial Intelligence
Kainova Therapeutics Press Mentions
Stay in the know about the latest news on Kainova Therapeutics
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
kainovatx • Apr 01, 2026
Kainova reports positive top line results from Phase I EPRAD trial
clinicaltrialsarena • Mar 12, 2026
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
biospace • Mar 10, 2026
Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors
pharmiweb • Mar 10, 2026
Reversing tumor immunosuppression with next-gen GPCR modulation
podcast • Mar 06, 2026
Kainova Therapeutics Management
Leadership team at Kainova Therapeutics
Board Member
Sylvie Ryckebusch
Board Observer
Guillaume Blavier
Join now and verify your accreditation status to gain access to:
- Kainova Therapeutics Current Valuation
- Kainova Therapeutics Stock Price
- Kainova Therapeutics Management
- Available deals in Kainova Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Kainova Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Kainova Therapeutics Revenue and Financials
- Kainova Therapeutics Highlights
- Kainova Therapeutics Business Model
- Kainova Therapeutics Risk Factors
- Kainova Therapeutics Research Report from SACRA Research
Trading Kainova Therapeutics Stock
How to invest in Kainova Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Kainova Therapeutics through EquityZen funds. These investments are made available by existing Kainova Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Kainova Therapeutics stock?
Shareholders can sell their Kainova Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."